Pharming Group (PHAR) Stock Chart & Stock Price History $10.04 -0.07 (-0.64%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Pharming Group Stock Price Performance The Pharming Group (PHAR) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 17.64%, with a year-to-date return of -0.25%. In the past month, the stock has decreased 11.17%, reflecting recent market activity. As of the latest close, Pharming Group traded at $10.10 with a market cap of $687.11 million and volume of 721 shares. Receive PHAR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-0.15%1 Month Performance-11.17%3 Month Performance+24.04%Year-To-Date Performance-0.25%1 Year Performance+17.64% PHAR Stock Chart for Wednesday, July, 16, 2025 PHAR Chart by TradingView Pharming Group Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/15/2025$10.35$10.10-2.42%$10.42$10.10721 shs$687.11 million07/14/2025$10.05$10.35+2.99%$10.35$10.31618 shs$704.12 million07/11/2025$9.98$10.05+0.75%$10.03$10.031,000 shs$683.71 million07/10/2025$10.01$9.98-0.35%$10.49$10.005,740 shs$678.60 million07/09/2025$10.16$10.01-1.48%$10.39$9.991,096 shs$680.98 million07/08/2025$10.47$10.16-2.96%$10.59$10.38747 shs$691.19 million07/07/2025$10.38$10.47+0.87%$9.88$9.88796 shs$712.27 million07/04/2025$10.38$10.38$10.58$10.41344 shs$706.16 million07/03/2025$10.65$10.38-2.54%$10.58$10.41344 shs$706.15 million07/02/2025$10.50$10.65+1.44%$10.69$10.522,238 shs$724.52 million Get the Latest News and Ratings for PHAR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. 07/01/2025$10.68$10.50-1.66%$10.71$10.71540 shs$714.25 million06/30/2025$10.83$10.68-1.39%$11.10$10.4633,193 shs$726.29 million06/27/2025$10.74$10.83+0.80%$11.49$10.495,739 shs$736.49 million06/26/2025$10.95$10.74-1.92%$11.27$10.414,524 shs$730.64 million06/25/2025$11.06$10.95-0.99%$11.00$10.79803 shs$744.94 million06/24/2025$10.49$11.06+5.48%$11.21$10.741,328 shs$752.41 million06/23/2025$10.60$10.49-1.08%$10.38$10.231,221 shs$713.30 million06/20/2025$11.19$10.60-5.27%$10.65$10.451,340 shs$721.13 million06/19/2025$11.19$11.19$10.95$10.741,914 shs$761.26 million06/18/2025$10.89$11.19+2.75%$10.95$10.741,914 shs$761.26 million06/17/2025$11.30$10.89-3.59%$11.14$11.051,129 shs$740.93 million06/16/2025$10.87$11.30+3.92%$11.50$11.285,054 shs$768.55 million Related Companies MOR Stock Chart CRNX Stock Chart ALVO Stock Chart HCM Stock Chart AMRX Stock Chart CPRX Stock Chart BHC Stock Chart OGN Stock Chart XENE Stock Chart MIRM Stock Chart Receive PHAR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PHAR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
